Novavax to Participate in the FBR New Prescriptions Conference
April 13 2016 - 4:05PM
GAITHERSBURG, Md., April 13, 2016
(GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage
vaccine company focused on the discovery, development and
commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced Stanley C. Erck, President and Chief
Executive Officer, will participate in a panel discussion at the
FBR Healthcare Series Conference New Prescriptions: Innovation in
the Treatment of Diseases and Infections.
Conference details are as
follows:
Date: Wednesday, April 20,
2016
Time: 9:30 a.m. U.S. Eastern Time
Location: J.W. Marriott Essex House, New York City
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage vaccine company committed to delivering novel
products to prevent a broad range of infectious diseases. Its
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are
the foundation for ground-breaking innovation that improves global
health through safe and effective vaccines. Additional information
about Novavax is available on the company's
website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#2003007
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024